
ELAN Stock Forecast & Price Target
ELAN Analyst Ratings
Bulls say
Elanco Animal Health demonstrates a robust market position, with its key product, Simparica Trio, maintaining a significant market share of over 50%, while the anticipated growth of Credelio Quattro from 12.8% to 16.8% by 2026 indicates strong competitive prospects. Additionally, notable year-over-year growth in the Advantage Family and Seresto products, reported at +33% and +28% respectively for the third quarter of 2025, underscores the company's effective product portfolio and healthy demand dynamics. These factors contribute to a fundamentally positive outlook for Elanco, suggesting resilience and growth potential in a competitive marketplace.
Bears say
Elanco Animal Health is facing potential near-term risks to earnings growth due to concerns surrounding its refinancing, particularly in light of Dentsply Sirona's recent high-interest bond offering. Despite achieving roughly 50% higher revenue, the company's EBITDA margin has declined by a couple of hundred basis points, indicating increased pressure on profitability. Additionally, the reported $28 million EBITDA outperformance in the second quarter may not be sufficient to offset these underlying financial challenges moving forward.
This aggregate rating is based on analysts' research of Elanco Animal Health Inc and is not a guaranteed prediction by Public.com or investment advice.
ELAN Analyst Forecast & Price Prediction
Start investing in ELAN
Order type
Buy in
Order amount
Est. shares
0 shares